Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)
Not Applicable
- Conditions
- Thyroid Cancer
- Interventions
- Other: follow up visit
- Registration Number
- NCT02156362
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
It is generally estimated that 5 % of patients with thyroid cancer will develop distant metastases, and most of them had an advanced stage of the disease at presentation. Thirty per cent of them are resistant to radio iodine therapy and are called "refractory". Their long term survival is estimated to be less than 10 %.
The objective of this study is to identify the factors associated with poor outcome in a cohort of patients with advanced thyroid cancer followed during 5 years. Anaplastic and medullary thyroid carcinomas were excluded.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 643
Inclusion Criteria
- Man or woman ≥ 18 years.
- Thyroid cancer differentiated from follicular origins (papillary, vesicular or poorly differentiated carcinoma).
- TNM classification: stage pT3 (≥2 cm), or pT4 or M1 at diagnosis.
- Patient after post operative radioiodine therapy.
Exclusion Criteria
- Patient who can not be followed during the protocol.
- Patient who does not consent.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description follow up follow up visit -
- Primary Outcome Measures
Name Time Method Rate of Thyroid cancer evolving to refractory stage 5 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hospices Civils de Lyon-Centre de Médecine Nucléaire Groupement Hospitalier Est 59 boulevard Pinel
🇫🇷Bron cedex, France